← Eichor
Study identifier: NCT06761209 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?

Condition: Auto-immune Hepatitis  ·  Sponsor: Centre Hospitalier Universitaire de la Guadeloupe

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Evaluate the proportion of seronegative auto-immune hepatitis and a possible relationship with the severity of the disease. Criteria of severity will be defined by corticodependance, corticoresistance and a severe form of the disease at diagnosis (cirrhosis or fulminant hepatitis). In case of predominant seronegative forms, other auto-antibodies related to this auto-immue hepatitis will be searched.

This description comes directly from the study's public registry record.

Talk to the study team

Valérie SOTER, Promotion Unit manager  ·  +590 590 934677  ·  valerie.soter@chu-guadeloupe.fr

Eunice NUBRET, Project manager  ·  +590 0590934686  ·  eunice.nubret@chu-guadeloupe.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Hospital of Saint-AntoineParis, France, FranceNot Yet Recruiting
CHU de Pointe-à PitrePointe à Pitre, Guadeloupe, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06761209